ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Venous Thromboembolism in Patients Hospitalized with COVID-19: Results from the Brazilian COVID-19 Registry

W.C. Silveira1, S.M. Rezende1, M.A.P. Martins1, M.C. Pires1, R.T. Silva1, L.E.F. Ramos1, M.V.R.S. Silva1, T.L.S. Sales2, C.C.R. Cimini3, M.H. Guimarães Júnior4, F.G. Aranha5, M.C.A. Nogueira6, L.B. Moreira7, T.O. Fereguetti8, P.L. Assaf9, M. Carneiro10, M.S. Marcolino1, S.F. Araújo11, A.V. Schwarbold12, G.A.N. Bastos13

1Federal University of Minas Gerais, Belo Horizonte, Brazil, 2Federal University of São João del-Rei, Divinópolis, Brazil, 3Hospital Santa Rosália, Teófilo Otoni, Brazil, 4Hospital Márcio Cunha, Ipatinga, Brazil, 5Hospital SOS Cárdio, Florianópolis, Brazil, 6Hospital Rede Mater Dei, Belo Horizonte, Brazil, 7Hospital das Clínicas de Porto Alegre, Porto Alegre, Brazil, 8Hospital Eduardo de Menezes, Belo Horizonte, Brazil, 9Hospital Metropolitano Doutor Célio de Castro, Belo Horizonte, Brazil, 10Hospital Santa Cruz, Santa Cruz do Sul, Brazil, 11Hospital Semper, Belo Horizonte, Brazil, 12Hospital Universitário de Santa Maria, Santa Maria, Brazil, 13Hospital Moinhos de Vento, Porto Alegre, Brazil

Abstract Number: PB1192

Meeting: ISTH 2021 Congress

Theme: Venous Thromboembolism » VTE Epidemiology

Background: COVID-19 patients are at increased risk of venous thromboembolism (VTE), and this complication leads to a worse prognosis. However, to diagnose VTE on COVID-19 patients is a challenge to physicians, as the symptoms of pulmonary embolism can often be mistaken for the overlapped viral pneumonia. Herein, there is still little information on VTE incidence and associated risk factors specifically for this population.

Aims: To assess the incidence and associated risk factors for VTE in hospitalized COVID-19 patients in Brazilian hospitals.

Methods: Retrospective multicenter cohort in 15 Brazilian hospitals. Consecutive adult patients (≥ 18 years-old) with laboratory-confirmed COVID-19 between March and September 2020 were included. Study data were collected from medical records using Research Electronic Data Capture (REDCap) tools. The study was approved by the National Research Ethics Commission waiving off the application of informed consent.

Results: Of 4,021 patients included, 234 (5.8%) had VTE. When comparing VTE and non-VTE groups (Tables 1 and 2), there was no statistical difference in terms of sex and age between groups. The median age was 63 years-old (IQR 51-72 years-old) in VTE group. The most common comorbidities for both groups were hypertension and diabetes. Obesity, chronic pulmonary obstructive disease, previous VTE and recent surgery were more frequent in VTE group. D-dimer, C-reactive protein, lactate dehydrogenase levels and lymphocyte count were higher in the VTE group. Admission to intensive care units (37.6% vs 69.7%; p < 0,001) and in-hospital mortality (19.0% vs 28.3%; p< 0,01) were significantly higher in those who had VTE.

Characteristic  Total Number no-VTE (n= 3,787) VTE (n = 234) p-value
Age (years)  4,021  61.0 (48.0, 72.0)  63.0 (51.0, 72.0)  0.161
Male sex at birth 4,020 2,098 (55.4%) 126 (53.8%) 0.689
Comorbidities        
Hypertension  4,021  2,059 (54.4%)  129 (55.1%)  0.874
COPD  4,021  228 (6.0%)  24 (10.3%)  0.014
Diabetes mellitus  4,021  1,068 (28.2%)  74 (31.6%)  0.293
Obesity (BMI ³ 30kg/m2)  4,021  683 (18.0%)  55 (23.5%)  0.044
Previous VTE  4,021  25 (0.7%)  5 (2.1%)  0.028
Surgery up to 90 days  4,015  89 (2.4%)  12 (5.1%)  0.016

Main demographic features of the COVID-19 hospitalized patients cohort   

Characteristic  Total No no-VTE (n= 3,787) VTE (n = 234)  p-value
Laboratory parameters        
D-dimer  3,275  2.0 (1.1, 7.8)  4.1 (1.5, 27.5)  <0.001 
C reactive protein (mg/L)  3,602  73.0 (33.7, 131.0)  92.3 (55.0, 172.1)  <0.001 
Lactate dehydrogenase  2,565  376.0 (273.0, 514.0)  407.0 (328.0, 603.0)  <0.001 
Leukocytes count  3,940  6.9 (5.1, 9.5)  8.7 (5.9, 12.4)  <0.001 
Outcomes        
In hospital mortality   4,013  719 (19.0%)  66 (28.3%)  <0.001 
Intensive care unit  4,017  1,424 (37.6%)  163 (69.7%)  <0.001 

Main clinical characteristics, laboratory-values and outcomes of the COVID-19 hospitalized patients cohort 

Conclusions: Overall, 5.8% of COVID-19 hospitalized patients had VTE. Elevated laboratory values were associated with increased risk of this condition. VTE was associated with higher rates of intensive care admission and in-hospital mortality.
 

To cite this abstract in AMA style:

Silveira WC, Rezende SM, Martins MAP, Pires MC, Silva RT, Ramos LEF, Silva MVRS, Sales TLS, Cimini CCR, Guimarães Júnior MH, Aranha FG, Nogueira MCA, Moreira LB, Fereguetti TO, Assaf PL, Carneiro M, Marcolino MS, Araújo SF, Schwarbold AV, Bastos GAN. Venous Thromboembolism in Patients Hospitalized with COVID-19: Results from the Brazilian COVID-19 Registry [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/venous-thromboembolism-in-patients-hospitalized-with-covid-19-results-from-the-brazilian-covid-19-registry/. Accessed June 25, 2022.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/venous-thromboembolism-in-patients-hospitalized-with-covid-19-results-from-the-brazilian-covid-19-registry/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley